Nieves Martínez Chanzá

Author

Also Known As

N. Martinez Chanza, N. Martinez‐Chanza, Nieves M. Chanza, Nieves MARTINEZ CHANZA, Nieves Martinez Chanza, Nieves Martinez Chanzá, Nieves Martinez-Chanza, Nieves Martínez Chanzá

Publications

876

Citations

H-Index

Concepts

All Affiliations

Dana-Farber Cancer Institute Institut Jules Bordet Brigham and Women's Hospital Huntsman Cancer Institute Emory University

About

Nieves Martínez Chanzá is an author at Dana-Farber Cancer Institute specializing in oncology, cancer research, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	219
2	Surgical Oncology	3	3	46
3	Cancer Therapeutics	3	3	202
4	Health Sciences	1	1	19
5	Pathology	1	1	10

Nieves Martínez Chanzá

Publications

686

Citations

H-Index

Page 1

	Year	Citations
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study Nieves Martínez Chanzá, Wanling Xie, Mehmet Asım Bilen, The Lancet Oncology UrologyGenitourinary CancerKidney ResearchMedicineRenal Pathology	2019	173
Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma Amin H. Nassar, Sarah Abou Alaiwi, Saud H. AlDubayan, Genetics in Medicine	2019	110
Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma Laure Hirsch, Nieves Martínez Chanzá, Subrina Farah, JAMA Oncology	2021	93
Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma Sarah Abou Alaiwi, Wanling Xie, Amin H. Nassar, Journal for ImmunoTherapy of Cancer	2020	82
Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas Jonathan Thouvenin, Omar Alhalabi, Maria I. Carlo, The Oncologist	2022	35
Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma Abhishek Tripathi, Edwin Lin, Wanling Xie, Journal for ImmunoTherapy of Cancer	2020	34
Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study Nieves Martínez Chanzá, Wanling Xie, Majd Issa, Journal for ImmunoTherapy of Cancer	2020	31
Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial) Nieves Martínez Chanzá, Louisa Soukane, Philippe Barthélémy, BMC Cancer	2021	19
Avelumab as the basis of neoadjuvant regimen in platinum-eligible and -ineligible patients with nonmetastatic muscle-invasive bladder cancer: AURA (Oncodistinct-004) trial. Nieves Martínez Chanzá, Aurélien Carnot, Philippe Barthélémy, Journal of Clinical Oncology Surgical OncologyCancer ManagementPharmacotherapyCisplatin Ineligible PtsOncology	2022	19
Metastatic renal cell carcinoma to the pancreas and other sites—a multicenter retrospective study Cassandra Duarte, Junxiao Hu, Benoit Beuselinck, EClinicalMedicine	2023	18

Page 1